APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis

Catalysts

About Pharming Group

Pharming Group focuses on rare disease treatments, with commercial therapies for hereditary angioedema and APDS and a late stage program in primary mitochondrial disease.

What are the underlying business or industry changes driving this perspective?

• Although Joenja is adding diagnosed APDS patients in the U.S. and has identified 54 pediatric patients aged 4 to 11, the ultra rare nature of the disease and reliance on priority review and label expansion mean any delay or smaller than expected pediatric uptake could temper the planned contribution to future revenue and earnings.
• Although recent Cell data suggest APDS prevalence may be far higher and labs are working on reclassifying variants of uncertain significance, the complex genetic work, need for KOL consensus and EMR based AI models could take longer than hoped to translate into treated patients, which may limit the pace of revenue growth from VUS reclassification.
• While the expansion into larger primary immunodeficiency and CVID indications through Phase II proof of concept basket trials could widen Joenja’s addressable market, the programs are still targeting readouts in the second half of 2026. Any inconclusive data or setbacks could therefore reduce expectations for longer term revenue and pressure margins tied to R&D spend.
• Although KL1333 for primary mitochondrial disease sits in a late stage registrational study with a prior positive futility analysis, the long path to an expected readout in late 2027 and inherent development risk mean this potential US$1b opportunity may not materialize as a future earnings driver if efficacy or safety data fall short.
• While RUCONEST continues to serve more severe and frequent HAE attack patients and is positioned as a key cash generator, planned withdrawal from certain ex U.S. markets and growing oral competition could cap patient growth over time. This may limit further expansion in gross profit and operating margin even with G&A reductions.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Pharming Group compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Pharming Group's revenue will grow by 3.1% annually over the next 3 years.
• The bearish analysts assume that profit margins will shrink from 3.3% today to 1.1% in 3 years time.
• The bearish analysts expect earnings to reach $4.4 million (and earnings per share of $0.05) by about July 2029, down from $12.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $34.0 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 553.5x on those 2029 earnings, up from 81.9x today. This future PE is greater than the current PE for the GB Biotechs industry at 42.7x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.71%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Pharming remains highly reliant on RUCONEST and Joenja as its two commercial assets, so any shift in treatment preferences in hereditary angioedema or APDS, competitive pressure from new oral or alternative therapies, or pricing and reimbursement changes in key markets could weigh on product uptake and slow revenue growth.
• The long timelines and clinical risk around KL1333 and the PID and CVID proof of concept programs mean that setbacks, delays, or weaker than hoped data could leave Pharming more dependent on its existing products for longer, which could limit future earnings expansion and pressure net margins as R&D spending continues.
• The company is withdrawing RUCONEST from some ex U.S. markets because those operations are not financially sustainable, and while management expects minimal impact, any misstep in execution, patient access issues, or reputational effects could reduce international revenue and dilute the benefit of recent gross margin gains.
• The APDS prevalence work, VUS reclassification efforts, and AI driven patient finding initiatives rely on external labs, KOL consensus and EMR data, so if these projects progress more slowly than hoped or identify fewer treatable patients than expected, Joenja’s longer term growth potential could be lower than implied and earnings could be lower than current expectations.
• Although management is emphasizing financial discipline, including G&A head count reductions and controlled operating expense growth, future M&A or pipeline expansion could still require sizeable cash outlays or integration costs that dilute returns, which could constrain free cash flow and compress net margins if revenue does not keep pace.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Pharming Group is €2.0, which represents up to two standard deviations below the consensus price target of €2.36. This valuation is based on what can be assumed as the expectations of Pharming Group's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €2.63, and the most bearish reporting a price target of just €2.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $405.0 million, earnings will come to $4.4 million, and it would be trading on a PE ratio of 553.5x, assuming you use a discount rate of 5.7%.
• Given the current share price of €1.25, the analyst price target of €2.0 is 37.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.